Astellas and Dr. Jen Ashton launch "Cooler Moments" to Spotlight Menopausal Hot Flashes and Empower Women to Advocate for Themselves
Astellas Pharma US has launched 'Cooler Moments' in partnership with Dr. Jen Ashton to address menopausal hot flashes and empower women's health advocacy. The initiative focuses on educating women about moderate to severe vasomotor symptoms (VMS) and available treatment options.
The campaign features Dr. Ashton hosting a video series to debunk menopause myths and discuss VEOZAH, a first-of-its-kind, FDA-approved, hormone-free treatment for reducing moderate to severe hot flashes and night sweats due to menopause. The program includes personal testimonials and aims to encourage open dialogue between women and healthcare providers about menopause management.
Astellas Pharma US ha lanciato 'Cooler Moments' in collaborazione con la Dott.ssa Jen Ashton per affrontare le vampate di calore in menopausa e promuovere la difesa della salute delle donne. L'iniziativa si concentra sull'educazione delle donne riguardo ai sintomi vasomotori (VMS) da moderati a gravi e alle opzioni di trattamento disponibili.
La campagna vede la Dott.ssa Ashton come ospite di una serie di video per sfatare i miti sulla menopausa e parlare di VEOZAH, un trattamento innovativo, approvato dalla FDA, senza ormoni per ridurre le vampate di calore e le sudorazioni notturne moderate a gravi dovute alla menopausa. Il programma include testimonianze personali e mira a incoraggiare un dialogo aperto tra donne e operatori sanitari sulla gestione della menopausa.
Astellas Pharma US ha lanzado 'Cooler Moments' en colaboración con la Dra. Jen Ashton para abordar los sofocos menopaúsicos y empoderar la defensa de la salud de las mujeres. La iniciativa se centra en educar a las mujeres sobre los síntomas vasomotores (VMS) de moderados a severos y sobre las opciones de tratamiento disponibles.
La campaña presenta a la Dra. Ashton como anfitriona de una serie de videos para desmentir mitos sobre la menopausia y discutir VEOZAH, un tratamiento sin hormonas, aprobado por la FDA, para reducir los sofocos y sudores nocturnos de moderados a severos debido a la menopausia. El programa incluye testimonios personales y tiene como objetivo fomentar un diálogo abierto entre las mujeres y los proveedores de atención médica sobre la gestión de la menopausia.
Astellas Pharma US는 Dr. Jen Ashton과 협력하여 'Cooler Moments'를 출시하여 폐경기 열감을 다루고 여성 건강 옹호를 강화합니다. 이 이니셔티브는 중등도에서 심각한 혈관 운동 증상(VMS)과 이용 가능한 치료 옵션에 대해 여성들을 교육하는 데 중점을 두고 있습니다.
이 캠페인에서는 Ashton 박사가 폐경에 대한 신화를 불식시키고 폐경으로 인한 중등도에서 심각한 열감과 야간 발한을 줄이기 위해 FDA 승인을 받은 최초의 호르몬 프리 치료제인 VEOZAH에 대해 논의하는 동영상 시리즈를 진행합니다. 이 프로그램은 개인적인 증언을 포함하며 여성과 의료 제공자 간의 폐경 관리에 대한 개방적인 대화를 장려하는 것을 목표로 합니다.
Astellas Pharma US a lancé 'Cooler Moments' en partenariat avec Dr. Jen Ashton pour aborder les bouffées de chaleur ménopausiques et renforcer l'engagement pour la santé des femmes. L'initiative se concentre sur l'éducation des femmes concernant les symptômes vasomoteurs (VMS) modérés à sévères et les options de traitement disponibles.
La campagne présente Dr. Ashton animant une série de vidéos pour démystifier la ménopause et discuter de VEOZAH, un traitement sans hormones, approuvé par la FDA, pour réduire les bouffées de chaleur et les sueurs nocturnes modérées à sévères dues à la ménopause. Le programme comprend des témoignages personnels et vise à encourager un dialogue ouvert entre les femmes et les prestataires de soins de santé sur la gestion de la ménopause.
Astellas Pharma US hat 'Cooler Moments' in Zusammenarbeit mit Dr. Jen Ashton gestartet, um Hitzewallungen in der Menopause zu behandeln und das Engagement für die Gesundheit von Frauen zu stärken. Die Initiative konzentriert sich darauf, Frauen über mäßige bis schwere vasomotorische Symptome (VMS) und verfügbare Behandlungsoptionen aufzuklären.
Die Kampagne enthält eine Videoserie mit Dr. Ashton, die Mythen über die Menopause entlarvt und VEOZAH diskutiert, eine erstmalige, von der FDA genehmigte, hormonfreie Behandlung zur Reduzierung von mäßigen bis schweren Hitzewallungen und Nachtschweißen aufgrund der Menopause. Das Programm beinhaltet persönliche Erfahrungsberichte und zielt darauf ab, einen offenen Dialog zwischen Frauen und Gesundheitsdienstleistern über das Management der Menopause zu fördern.
- Launch of FDA-approved VEOZAH, a first-of-its-kind hormone-free treatment for menopausal symptoms
- Strategic partnership with prominent women's health expert Dr. Jen Ashton
- Market expansion into women's health segment addressing unmet medical needs
- None.
"Cooler Moments" educates and empowers women in midlife to speak up for themselves and celebrate this natural change in their lives.
Experience the full interactive Multichannel News Release here:
https://www.multivu.com/astellas_pharma/9261451-en-astellas-jen-ashton-launch-cooler-moments-spotlight-menopausal-hot-flashes
This effort shines light on the millions of women in the
As part of Cooler Moments, Dr. Ashton will host a video series and speak to women live to debunk myths about menopause, break down the science, and encourage them to advocate for themselves when it comes to hot flashes and night sweats due to menopause. She will also speak with Kris, a woman with moderate to severe hot flashes and night sweats, about her personal experience and how she was able to manage her symptoms with VEOZAH™.3 VEOZAH is a first-of-its-kind, FDA-approved,
Do not use VEOZAH if you have cirrhosis, have severe kidney problems or kidney failure, or are taking certain medicines called CYP1A2 inhibitors.3 Please see additional Important Safety Information below.
Dr. Jen Ashton, Board-Certified OBGYN, Former Chief Medical Correspondent
"I'm honored to partner with Astellas to help inspire conversation about hot flashes and night sweats due to menopause and treatment options. Managing these symptoms is not one-size-fits-all, and women should feel comfortable having an open dialogue with their healthcare providers to create a plan that's right for them. As a doctor, I've seen how hot flashes due to menopause can significantly impact women, and I know how important it is women are counseled about all of their options, both hormonal and nonhormonal.2 Many women and doctors alike may not know that there are nonhormonal treatment options such as VEOZAH available, especially for women who cannot or choose not to take hormones.3 We are at a pivotal time to elevate cultural and medical conversations around hot flashes, night sweats, and menopause in a way that is backed in science and informed by the latest data, and to do so without judgment, fear or stigma."
Ben Ormsbee,
"Astellas is committed to elevating the conversation around hot flashes and night sweats due to menopause to help ensure women are informed and empowered to seek the support they need to make the best decision for their menopause journey. We're thrilled to launch Cooler Moments with Dr. Ashton, a leading women's health expert, to encourage women to not settle and to advocate for their own health."
Cooler Moments builds on the work that Astellas launched earlier this year with Emmy- and Golden Globe-nominated actress Gloria Reuben, who has experienced moderate to severe VMS due to menopause first-hand and has had fewer and less severe hot flashes and night sweats thanks to VEOZAH.3 Individual results may vary. Women should talk to their doctor about what it could mean to them.
Visit VEOZAH.com for more information about moderate to severe VMS due to menopause, including Gloria Reuben's personal journey with VMS due to menopause, tips for how to have an informed conversation with your healthcare provider, and all there is to know about VEOZAH.
About VEOZAH (fezolinetant)
VEOZAH (fezolinetant) is a neurokinin 3 (NK3) receptor antagonist approved in the
About Vasomotor Symptoms due to Menopause
VMS, characterized by hot flashes (also called hot flushes) and/or night sweats, are common symptoms of menopause.1 In the
Do not use VEOZAH if you:
- have cirrhosis.
- have severe kidney problems or kidney failure.
- are taking certain medicines called CYP1A2 inhibitors. Ask your healthcare provider if you are not sure.
Before you use VEOZAH, tell your healthcare provider about all of your medical conditions, including if you:
- have liver disease or problems.
- have kidney problems.
- have any medical conditions that may become worse while you are using VEOZAH.
Tell your healthcare provider about all the medicines you take, including prescription and over-the- counter medicines, vitamins, and herbal supplements. VEOZAH may affect the way other medicines work, and other medicines may affect how VEOZAH works.
VEOZAH can cause serious side effects, including:
- increased liver blood test values and liver problems. Your healthcare provider will do a blood test to check your liver before you start taking VEOZAH. Your healthcare provider will also do this blood test monthly for the first 3 months, at month 6, and month 9 after you start taking VEOZAH or if you have signs or symptoms that suggest liver problems. If your liver blood test values are elevated, your healthcare provider may advise you to stop treatment or request additional liver blood tests.
Stop VEOZAH and call your healthcare provider right away if you have the following signs or symptoms of liver problems:
- feeling more tired than you do usually
- nausea
- vomiting
- itching
- yellowing of the eyes or skin (jaundice)
- pale feces
- dark urine
- pain in the right upper stomach (abdomen)
The most common side effects of VEOZAH include:
- stomach (abdominal) pain
- diarrhea
- difficulty sleeping (insomnia)
- back pain
- hot flashes or hot flushes
These are not all the possible side effects of VEOZAH. Tell your healthcare provider if you have any side effect that bothers you or does not go away.
Call your healthcare provider for medical advice about side effects. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800- FDA-1088.
For more information, please see the full Prescribing Information and Patient Product Information for VEOZAH (fezolinetant).
About Astellas
Astellas Pharma Inc. is a pharmaceutical company conducting business in more than 70 countries around the world. We are promoting the Focus Area Approach that is designed to identify opportunities for the continuous creation of new drugs to address diseases with high unmet medical needs by focusing on Biology and Modality. Furthermore, we are also looking beyond our foundational Rx focus to create Rx+® healthcare solutions that combine our expertise and knowledge with cutting-edge technology in different fields of external partners. Through these efforts, Astellas stands on the forefront of healthcare change to turn innovative science into VALUE for patients. For more information, please visit our website at https://www.astellas.com/en.
Cautionary Notes
In this press release, statements made with respect to current plans, estimates, strategies and beliefs and other statements that are not historical facts are forward-looking statements about the future performance of Astellas. These statements are based on management's current assumptions and beliefs in light of the information currently available to it and involve known and unknown risks and uncertainties. A number of factors could cause actual results to differ materially from those discussed in the forward-looking statements. Such factors include, but are not limited to: (i) changes in general economic conditions and in laws and regulations, relating to pharmaceutical markets, (ii) currency exchange rate fluctuations, (iii) delays in new product launches, (iv) the inability of Astellas to market existing and new products effectively, (v) the inability of Astellas to continue to effectively research and develop products accepted by customers in highly competitive markets, and (vi) infringements of Astellas' intellectual property rights by third parties. Information about pharmaceutical products (including products currently in development) which is included in this press release is not intended to constitute an advertisement or medical advice.
References:
1 Thurston RC. Vasomotor symptoms. In: Crandall CJ, Bachman GA, Faubion SS, et al., eds. Menopause Practice: A Clinician's Guide. 6th ed.
2 English M, Stoykova B, Slota C, et al. Qualitative study: burden of menopause-associated vasomotor symptoms (VMS) and validation of PROMIS sleep disturbance and sleep-related impairment measures for assessment of VMS impact on sleep. J Patient Rep Outcomes 2021;5(37):1-13. Erratum in: J Patient Rep Outcomes 2021;5:42
3 Veozah [package insert].
4 The North American Menopause Society. The 2023 nonhormone therapy position statement of the North American Menopause Society. Menopause. 2023;30(6):573-590.
5 FFreeman EW, Sammel MD, Sanders RJ. Risk of long-term hot flashes after natural menopause: evidence from the Penn Ovarian Aging Study cohort. Menopause. 2014;21(9):924-932.
View original content:https://www.prnewswire.com/news-releases/astellas-and-dr-jen-ashton-launch-cooler-moments-to-spotlight-menopausal-hot-flashes-and-empower-women-to-advocate-for-themselves-302323882.html
SOURCE Astellas Pharma Inc.
FAQ
What is the new Astellas Pharma (ALPMY) menopause treatment campaign called?
What is VEOZAH, Astellas Pharma's (ALPMY) new menopause treatment?
Who is partnering with Astellas Pharma (ALPMY) for the Cooler Moments campaign?
